Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Swiss Restless Legs Syndrome Trial (SRLS) A Double-blind, Randomised, Crossover Trial Investigating the Efficacy and Safety of the Dopamine Agonist Pramipexole (Sifrol®, 0.25-0.75 mg Per Day) Versus Levodopa / Benserazide (Madopar® DR, 125-375 mg Per Day) in Patients With Restless Legs Syndrome

NCT00144209 is registered in ClinicalTrials.gov with Boehringer Ingelheim as lead sponsor.

NCT NCT00144209
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00144209 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Swiss Restless Legs Syndrome Trial (SRLS) A Double-blind, Randomised, Crossover Trial Investigating the Efficacy and Safety of the Dopamine Agonist Pramipexole (Sifrol®, 0.25-0.75 mg Per Day) Versus Levodopa / Benserazide (Madopar® DR, 125-375 mg Per Day) in Patients With Restless Legs Syndrome
Lead sponsor
Boehringer Ingelheim
Phase
Phase 3
Overall status
Completed
Start date
February 28, 2003
Completion date
February 28, 2005
Enrollment
58 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

restless legs syndrome